Immune checkpoint inhibitors (ICIs) have revolutionised solid cancer treatment, but many patients still do not benefit. While ICIs release the brakes on T cells, they do not address the underlying tumour antigen presentation that is often insufficient to activate robust, polyclonal T cell immunity. Monocyte-derived DCs (Mo-DCs) were, and still are, the focus of cellular immunotherapies being developed to solve cancer antigen-presentation. Decades of evidence in mouse, and more recently in humans, suggest that Mo-DCs are suboptimal for priming anti-tumour T cells. In contrast, type 1 conventional DCs (DC1s) are vastly superior: they excel at cross-presentation of exogenous tumour antigens via MHC Class I and drive strong cytotoxic CD8+ T cell responses. DC1s are rare, however - only 1-20 million DC1s can be isolated from a two-blood volume leukapheresis. We have developed a manufacturing method capable of generating ~1 billion DC1s from a single bag of G-CSF mobilised apheresis, making multiple dosing of a future autologous DC1 therapy feasible. Off-the-shelf allogeneic DC1s are also being pursued in parallel for a more streamlined cost-effective approach. Lastly, we are developing novel DC-specific Chimeric Antigen Receptors to enhance antigen presentation only upon tumour encounter. We plan to initiate clinical trials in solid cancers using DC1s within 2-3 years, addressing ICI limitations and enabling more patients to benefit from DC immunotherapy.